BlueRock Therapeutics
238 Main Street, 3rd Floor
Cambridge
MA
02142
United States
Tel: 1-857-299-7589
Website: https://bluerocktx.com/about/
Email: hr@bluerocktx.com
About BlueRock Therapeutics
BlueRock Therapeutics is a leading engineered cell therapy company with a mission to develop regenerative medicines for intractable diseases. BlueRock Therapeutics’ cell+gene platform harnesses the power of cells to create new medicines for neurology, cardiology, and immunology indications.
BlueRock Therapeutics’ cell differentiation technology recapitulates the cell’s developmental biology to produce authentic cell therapies, which are further engineered for additional function. Utilizing these cell therapies to replace damaged or degenerated tissue brings the potential to restore or regenerate lost function.
BlueRock’s culture is defined by scientific innovation, the highest ethical standards and an urgency to bring transformative treatments to all who would benefit. The company strives to be a top employer of scientific talent, empowering every member of the team to make meaningful and lasting contributions to the burgeoning field of regenerative medicine.
Become a BlueRocker! We are expanding our BlueRock team at all locations. Contact us on our website to learn about rewarding career opportunities.
Our CEO, Seth Ettenberg, talking about the importance of Community at BlueRock.
54 articles about BlueRock Therapeutics
-
BlueRock Therapeutics, FUJIFILM Cellular Dynamics, and Opsis Therapeutics Enter into a Strategic R&D Alliance to Discover and Develop Cell Therapies for Eye Diseases
5/17/2021
BlueRock Therapeutics LP, a clinical stage biopharmaceutical company and wholly-owned subsidiary of Bayer AG, FUJIFILM Cellular Dynamics, Inc. a leading global developer and manufacturer of human induced pluripotent stem (iPS) cell technologies, and Opsis Therapeutics, LLC, a joint venture of FUJIFILM Cellular Dynamics (FCDI) and David Gamm, M.D., Ph.D., co-founder
-
BlueRock Therapeutics Receives Permission from Health Canada for DA01 Trial in Parkinson's Disease
4/7/2021
BlueRock Therapeutics LP, a clinical stage biopharmaceutical company and wholly-owned subsidiary of Bayer AG, announced that Health Canada has given permission to initiate "Phase 1 Safety and Tolerability Study of MSK-DA01 Cell Therapy for Advanced Parkinson's Disease (PD)."
-
BlueRock Therapeutics Appoints Seth Ettenberg, Ph.D. Chief Scientific Officer
3/3/2020
BlueRock Therapeutics, LP today announced the addition of Seth Ettenberg, Ph.D. to the company’s senior leadership team.
-
Here’s a look at the top three companies from the “Top 20 Life Science Startups to Watch in 2018.”
-
BlueRock Therapeutics to Present at 2019 Cell & Gene Meeting on the Mesa
9/25/2019
BlueRock Therapeutics, today announced that Emile Nuwaysir, Ph.D., Chief Executive Officer of BlueRock and Vice Chairman of the Alliance for Regenerative Medicine (ARM), will present at the Cell & Gene Meeting on the Mesa, to be held Oct. 2-4 in Carlsbad, Calif.
-
Versant Ventures Announces Acquisition of Cell Therapy Company BlueRock Therapeutics
8/8/2019
Another successful outcome from a Versant-created company in a breakthrough field
-
Bayer acquires BlueRock Therapeutics to build leading position in cell therapy
8/8/2019
Bayer AG and BlueRock Therapeutics announced an agreement under which Bayer will fully acquire BlueRock Therapeutics, a privately held US-headquartered biotechnology company focused on developing engineered cell therapies in the fields of neurology, cardiology and immunology, using a proprietary induced pluripotent stem cell platform.
-
Under the terms of the acquisition, Bayer is buying the rest of the company for $240 million up front with an additional $360 million in various development milestones. This will correspond with the company’s value of about $1 billion.
-
BlueRock Therapeutics to Participate at Upcoming Conferences - May 23, 2019
5/23/2019
BlueRock Therapeutics, LP, an engineered cell therapy company leveraging its novel CELL+GENE™ platform to develop regenerative medicines for intractable diseases, announced that the company will present at the following upcoming conferences.
-
BlueRock Therapeutics to Present at 2019 Cell & Gene Meeting on the Mediterranean
4/18/2019
BlueRock Therapeutics, LP announced its participation in the inaugural Cell & Gene Meeting on the Mediterranean to be held April 23-25 in Barcelona, Spain.
-
Cambridge, Mass.-based Editas Medicine and privately-held BlueRock Therapeutics have teamed up and combined their genome editing and cell therapy technologies to discover, develop and manufacture novel engineered cell medicines.
-
BlueRock Therapeutics Appoints Joachim Fruebis, Ph.D., as Chief Development Officer
3/18/2019
Strengthens executive team with drug development expertise to translate novel Cell+Gene platform into therapeutic programs
-
BlueRock Therapeutics to Present at Cowen and Company 39th Annual Health Care Conference
3/5/2019
BlueRock Therapeutics, LP announced that Emile Nuwaysir, Ph.D., Chief Executive Officer of BlueRock Therapeutics, will present at the Cowen and Company 39th Annual Health Care Conference on Tuesday, March 12, 2019, at 4:30 p.m. ET at the Boston Marriott Copley Place.
-
BlueRock Therapeutics Establishes Key Partnerships with Leading Experts in Autoimmune Disease
1/16/2019
BlueRock Therapeutics, LP, an engineered cell therapy company leveraging its novel Cell+Gene platform to develop regenerative medicines for intractable diseases, today announced the establishment of partnerships with Bruce Blazar, M.D., Regents Professor of Pediatrics, Division of Blood and Marrow Transplantation at the University of Minnesota
-
BlueRock Therapeutics to Present at the 37th Annual JP Morgan Healthcare Conference
1/2/2019
BlueRock Therapeutics an engineered cell therapy company leveraging its novel Cell+Gene platform to develop regenerative medicines for intractable diseases, today announced that Emile Nuwaysir, President and Chief Executive Officer, will present at the 37th Annual J.P. Morgan Healthcare Conference on Wednesday, Jan. 9, 2019 at 10:30 a.m. PT / 1:30 p.m. ET at the Westin St. Francis Hotel in San Francisco.
-
Readers' Picks: Top 10 Stories of 2018
12/28/2018
As we look back over the year, we noticed some stories just grabbed readers more than others. Here’s a look at the top 10 stories of the year, including job cuts, best-selling drugs, up-and-coming companies,scandals, clinical trials, and more. -
BlueRock Therapeutics Strengthens Collaboration with the McEwen Stem Cell Institute
12/6/2018
The partnership encompasses an operations and infrastructure expansion. BlueRock will be moving into an additional 14,000 square feet within UHN in Toronto's MaRS Discovery District, co-located with the McEwen Institute.
-
BlueRock Therapeutics Appoints Min Wang, J.D., Ph.D., as Chief Legal and Administrative Officer
11/26/2018
BlueRock Therapeutics, LP, an engineered cell therapy company leveraging its novel Cell+Gene platform to develop regenerative medicines for intractable diseases, today announced the appointment of Min Wang, J.D., Ph.D., as Chief Legal and Administrative Officer.
-
BlueRock Therapeutics to Participate at Upcoming Conferences
11/7/2018
BlueRock Therapeutics, LP, an engineered cell therapy company leveraging its novel Cell+Gene platform to develop regenerative medicines for intractable diseases, today announced that the company will present at the following upcoming conferences
-
BlueRock Therapeutics President and CEO Emile Nuwaysir elected to serve as Vice Chairman of the Alliance for Regenerative Medicine
10/3/2018
BlueRock Therapeutics, LP announced today that Dr. Emile Nuwaysir, the Company's President and Chief Executive Officer, has been elected Vice Chairman of the Alliance for Regenerative Medicine (ARM), an international organization representing the cell and gene therapies community.